Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news


From To
Desperate patients turn to buyers clubs

What do you do when the NHS won’t buy the treatment you need?

25 June 2019
The Economist (free registration required)
Cash Incentives, Peer Support May Not Incentivize HCV Treatment

A randomized trial comparing a cash incentive to peer support for increasing acceptance of treatment for hepatitis C virus (HCV) among persons with HCV/HIV coinfection, including those who use drugs or alcohol, found both methods helpful but that 1 in 4 patients still declined treatment.

10 May 2019
MD Magazine
England hits WHO 2020 hepatitis C target three years early

Deaths from liver disease related to serious hepatitis C (HCV) fell by more than 16% between 2015 and 2017, according to data published by Public Health England (PHE). As a result, England has hit the World Health Organization’s (WHO’s) target to reduce HCV related mortality by 10% by 2020 three years early.

18 April 2019
The Pharmaceutical Journal
Hepatitis C drugs for all genotypes curing almost everyone who completes treatment, real-world studies show

Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment

16 April 2019
Keith Alcorn
Summary from CROI 2019 for viral Hepatitis, from Jürgen Rockstroh

Although no new drugs for HBV or HCV therapy were presented a whole range of important clinical studies were discussed which all have important clinical implications for daily practice.

09 April 2019
Hepatitis C deaths fall by 16 per cent between 2015 and 2017

Deaths from serious hepatitis C related liver disease fell by 16.1% between 2015 and 2017 according to data from PHE.

09 April 2019
Public Health England
Armenia gets license to produce drugs for hepatitis C treatment

The Armenian Ministry of Health and the Gilead Science Ireland UC have signed a Memorandum of Understanding, under which Gilead will provide Armenia with a license to produce, pack and import genetic drugs for hepatitis C treatment.

03 April 2019
Public Radio of Armenia
San Francisco Study Shows Engagement in HCV Care Aids Elimination

In San Francisco, many transwomen have access to hepatitis C virus (HCV) testing and treatment, which suggests an opportunity for HCV control and elimination, according to a study recently published in the Journal of Viral Hepatitis.

02 April 2019
Infectious Disease Advisor
EACS Standard of Care meeting report – Tackling HIV and co-infections in Europe: towards common standards

This is the full report from the EACS Standard of Care Meeting. It can also be read in three separate sections here.Eastern Europe continues to have

29 March 2019
Gus Cairns
Louisiana picks drug company for hepatitis C treatment plan

Gilead Sciences subsidiary Asegua Therapeutics LLC won the contract, selected from three companies that sought to partner with the state. Louisiana will pay a fee to the drug manufacturer for unlimited access to its hepatitis C medication, a generic version of Epclusa, for five years.

27 March 2019
San Francisco Chronicle
← First12345...106Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.